Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials

Department of Internal Medicine III, Division of Nephrology, Medical University Vienna, Vienna, Austria.
Nephrology Dialysis Transplantation (Impact Factor: 3.49). 09/2006; 21(8):2275-81. DOI: 10.1093/ndt/gfl104
Source: PubMed

ABSTRACT Bone loss remains a serious problem after kidney transplantation and is most pronounced during the first months after engraftment. Bisphosphonates are frequently used to treat post-transplant osteodystrophy, but data of large randomized controlled trials (RCTs) are missing.
We, therefore, conducted this systematic review of the literature, searching electronic databases, reference lists and abstracts from scientific meetings to identify RCTs in all languages. The primary outcome assessed was the change in bone mineral density (BMD) during the early post-transplantation period. Based on the mean BMD change presented in the identified publications, the authors were asked for the individual BMD results of all randomized patients, determined at lumbar spine and femoral neck before and after bisphosphonate therapy. Data were pooled for summary estimates by using weighted mean differences of absolute change in BMD. An analysis of covariance was performed, adjusted for individual baseline values, treatment arm and individual trial.
Five studies involving 180 participants were included in our meta-analysis. Treatment with bisphosphonates showed a substantial effect in preventing post-transplant osteodystrophy. BMD decline at the lumbar spine within 6-12 months after transplantation was significantly reduced by 0.06 g/cm(2) in patients treated with bisphosphonates (95% CI 0.05-0.08 g/cm(2)). At the femoral neck, the loss of BMD was reduced by 0.05 g/cm(2) during this period (95% CI 0.0-0.11 g/cm(2)), reaching just non-statistical significance. This benefit of bone loss prevention could be reached without major side effects.
Bisphosphonates are effective in preventing bone loss in the early post-transplant period.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone loss and fracture are serious sequelae of kidney transplantation, associated with morbidity, mortality and high economic costs. The pathogenesis of post-transplantation bone loss is multifactorial and complex. Pre-existing bone mineral disease is responsible for a significant part, but it is aggravated by risk factors emerging after renal transplantation with immunosuppressive agents being one of the key contributors. The decrease in bone mass is particularly prominent during the first 6-12 months after transplantation, continuing at a lower rate thereafter. Bone mineral density measurements do not predict bone histology and bone biopsy findings reveal heterogeneous lesions, which vary according to time after transplantation. Currently, vitamin D and bisphosphonates are the most extensively tested therapeutic agents against this accelerated bone loss in renal transplant recipients. Both of these agents have proven effective, but there is no evidence that they decrease fracture risk. More studies are needed to examine the complex pathophysiologic mechanisms implicated in this population, as well as the effects of different therapeutic interventions on bone disorders after kidney transplantation.
    International Urology and Nephrology 11/2014; 47(3). DOI:10.1007/s11255-014-0862-3 · 1.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The overall effect of pamidronate on bone mass density (BMD) in the early renal transplant period varies considerably among studies. The effects of pamidronate on graft function have not been determined. Materials and Methods A comprehensive search was conducted in PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase independently by two authors. Randomized controlled trials of pamidronate evaluating bone loss in the first year of renal transplantation were included. Methods reported in the “Cochrane Handbook for Systematic Reviews of Interventions 5.0.2” were used to evaluate changes of lumbar spine and femoral neck BMD, and serum creatinine, calcium and intact parathyroid hormone (iPTH) levels. Fixed or random effect models were used as appropriate. Results Six randomized trials evaluating 281 patients were identified. One hundred forty-four were treated with pamidronate and 137 were control patients. Administration of pamidronate was associated with significant reduction of bone loss in the lumbar spine, compared to the control group (standardized mean difference (SMD) = 24.62 [16.25, 32.99]). There was no difference between the pamidronate treated and control femoral neck BMD (SMD = 3.53 [−1.84, 8.90]). A significant increase in the serum creatinine level of the intervention group was seen, compared to the control group. The serum calcium and iPTH of the pamidronate and control groups were not different after 1 year (serum creatinine: SMD = −3.101 [−5.33, −0.89]; serum calcium: SMD = 2.18 [−0.8, 5.16]; serum iPTH: SMD = 0.06 [−0.19, 0.31]). Heterogeneity was low for serum calcium and iPTH and high for serum creatinine. Conclusions This meta-analysis demonstrated the beneficial clinical efficacy of pamidronate on BMD with no association with any alteration in graft function during the first year of renal transplantation. Significant heterogeneity precludes the conclusion of the relationship between serum creatinine and pamidronate.
    PLoS ONE 09/2014; 9(9):e108106. DOI:10.1371/journal.pone.0108106 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Kidney transplantation reverses some of the disturbances of mineral and bone metabolism. However, the reversal or degree of improvement is often incomplete. The well-documented bone loss, especially in the early posttransplant period, contributes to an increased incidence of fractures in kidney transplant recipients. To better understand the mechanism of bone loss posttransplant, we need to take in consideration both bone quantity (density) and quality (bone microarchitecture, turnover rate). In addition to bone density, which is a measure of bone quantity, there are other invasive and noninvasive tools that provide information about the bone architecture and turnover and may be helpful in evaluating kidney transplant recipients at risk of fractures. There are several factors that contribute to the development of bone loss in the posttransplant period. Among these, the use of glucocorticoids, as part of the posttransplant immunosuppressive regimen, remains the single most important risk factor for bone loss post–kidney transplant. Interventions for evaluation and management of bone disease posttransplant are described and discussed. Some of these measures have been shown to increase bone density, but so far, none have demonstrated an ability to reduce the fracture incidence.
    Transplantation Reviews 07/2007; 21(3):143-154. DOI:10.1016/j.trre.2007.05.001 · 2.68 Impact Factor